MC2 Therapeutics Announces Positive Phase 2a Results of
MC2-32 (RGRN-305) a first in class, oral therapy targeting multiple pathways involved in Hidradenitis Suppurativa (HS) achieves highly positive data in...
Source: globenewswire.com
Lars Iversen News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Lars Iversen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Lars Iversen Today - Breaking & Trending Today
MC2 Therapeutics Announces Positive Phase 2a Results of Novel HSP90 Inhibitor for Hidradenitis ...
MC2-32 (RGRN-305) a first in class, oral therapy targeting multiple pathways involved in Hidradenitis Suppurativa (HS) achieves highly positive data in randomized, double-blinded, placebo-controlled trial in 15 patients:Primary endpoint, HiSCR50
Source: eagletribune.com
MC2 Therapeutics Acquires Option to Phase 2 Oral Drug Candidate for Hidradenitis Suppurativa and Other Indications
MC2 Therapeutics Acquires Option to Phase 2 Oral Drug Candidate for Hidradenitis Suppurativa and Other IndicationsOption to exclusively license the rights to develop, manufacture and commercialize “RGRN-305” for all human indications, incl. oral treatment of Hidradenitis Suppurativa (“HS”)RGR...
Source: pharmiweb.com
MC2 Therapeutics Acquires Option to Phase 2 Oral Drug Candidate for Hidradenitis Suppurativa and Oth
Option to exclusively license the rights to develop, manufacture and commercialize “RGRN-305” for all human indications, incl. oral treatment of Hidradenitis Suppurativa (“HS”)RGRN-305 is a new chemical entity having a novel mode of action targeting HSClinical data from a double-blinded placebo-controlled Ph2a trial...
Source: pharmiweb.com
MC2 Therapeutics bags license rights for hidradenitis suppurativa drug
MC2 Therapeutics has acquired the exclusive licensing rights for Regranion’s RGRN-305, a new treatment for hidradenitis suppurativa (HS).
Source: biopharma-reporter.com